Analysts Set Expectations for Reviva Pharmaceuticals Holdings, Inc.’s Q1 2025 Earnings (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Reviva Pharmaceuticals in a report released on Monday, April 22nd. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.33) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.24) EPS and Q4 2025 earnings at ($0.21) EPS.

Separately, Benchmark reissued a “speculative buy” rating and issued a $17.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, April 16th.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ:RVPH opened at $3.02 on Tuesday. The business’s 50-day moving average is $3.57 and its 200-day moving average is $4.10. Reviva Pharmaceuticals has a 1 year low of $2.67 and a 1 year high of $9.25. The company has a market capitalization of $84.32 million, a price-to-earnings ratio of -1.84 and a beta of -0.02.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RVPH. Vontobel Holding Ltd. bought a new position in shares of Reviva Pharmaceuticals in the fourth quarter valued at $72,000. EMC Capital Management lifted its position in Reviva Pharmaceuticals by 1,294.3% in the 3rd quarter. EMC Capital Management now owns 123,915 shares of the company’s stock valued at $613,000 after acquiring an additional 115,028 shares in the last quarter. Finally, Armistice Capital LLC boosted its stake in Reviva Pharmaceuticals by 194.0% during the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock valued at $9,085,000 after purchasing an additional 1,164,000 shares during the last quarter. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.